Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Universitätsklinikum Hamburg-Eppendorf |
---|---|
Information provided by: | Universitätsklinikum Hamburg-Eppendorf |
ClinicalTrials.gov Identifier: | NCT00858793 |
Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
Condition | Intervention | Phase |
---|---|---|
AIDS-Related Lymphoma HIV Infections |
Procedure: PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | High-Dose Chemotherapy With Transplantation of Gene-Modified Stem Cells for High-Risk AIDS-Related Lymphoma |
Estimated Enrollment: | 10 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | October 2016 |
Estimated Primary Completion Date: | October 2015 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Procedure: PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)
Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Any of the following conditions:
Contact: Axel R Zander, Prof. Dr. Dr. | +49-40-7410-54850 | zander@uke.uni-hamburg.de |
Germany | |
University Medical Center Hamburg-Eppendorf | Recruiting |
Hamburg, Germany, 20246 | |
Contact: Axel R Zander, Prof. Dr. Dr. +49-40-7410-54850 zander@uke.uni-hamburg.de | |
Contact: Marion Heinzelmann, R. N. +49-40-7410-54188 mheinzel@uke.uni-hamburg.de | |
Principal Investigator: Axel R Zander, Prof. Dr. Dr. | |
Sub-Investigator: Jan van Lunzen, PD Dr. | |
Sub-Investigator: Alex Zoufaly, Dr. |
Responsible Party: | University Medical Center Hamburg-Eppendorf ( Prof. Dr. Dr. A. R. Zander ) |
Study ID Numbers: | ARL-GT 2005 |
Study First Received: | March 9, 2009 |
Last Updated: | April 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00858793 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Germany: Paul-Ehrlich-Institut |
AIDS HIV Lymphoma |
Stem Cell Transplantation gene-modified Stem Cells treatment experienced |
Lymphoma, AIDS-related Sexually Transmitted Diseases, Viral Immunoproliferative Disorders Acquired Immunodeficiency Syndrome Antiviral Agents Immunologic Deficiency Syndromes Virus Diseases Lymphoma, B-Cell Lymphatic Diseases |
B-cell Lymphomas Lymphoma, AIDS-Related HIV Infections Sexually Transmitted Diseases Primary Effusion Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma Retroviridae Infections |
RNA Virus Infections Sexually Transmitted Diseases, Viral Immunoproliferative Disorders Neoplasms by Histologic Type Slow Virus Diseases Immune System Diseases Acquired Immunodeficiency Syndrome Infection Immunologic Deficiency Syndromes Lymphoma, B-Cell Virus Diseases |
Lymphatic Diseases Neoplasms Lymphoma, AIDS-Related HIV Infections Sexually Transmitted Diseases Lentivirus Infections Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Lymphoma Retroviridae Infections |